Acid Ceramidase Mixture for Sustained Therapeutic Effect
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for acid ceramidase-related disorders are limited by the short half-life of fully active acid ceramidase, which can impact cell survival and phenotype improvement.
Innovation Solution
A therapeutic composition comprising a ceramidase mixture with a higher ratio of inactive acid ceramidase precursor to active enzyme, which is more effective in promoting cell survival and improving cell phenotype, is developed. This composition is produced by incubating a medium containing the inactive precursor under conditions that transform a portion of it into active acid ceramidase.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fully active acid ceramidase is used for therapy, then immediate enzymatic activity is achieved, but the short half-life limits sustained effectiveness
Solution Approach 1:
The patent applies preliminary action by pre-incubating the inactive acid ceramidase precursor under conditions that promote partial transformation to active enzyme before administration. This creates a reservoir of active enzyme that will continue to be generated in vivo, extending the therapeutic duration. The precursor is prepared in advance with controlled activation to achieve optimal initial activity while maintaining prolonged presence in the body.
Solution Approach 2:
The patent changes the physical-chemical parameters of the ceramidase preparation by controlling the ratio of inactive precursor to active enzyme through incubation conditions (pH, temperature, time). By adjusting these parameters, the formulation achieves a balance between immediate therapeutic activity and extended duration, as the inactive precursor serves as a sustained-release reservoir that converts to active enzyme in vivo.
2Duration of action of moving object
If inactive acid ceramidase precursor is administered, then longer half-life and sustained release are achieved, but immediate therapeutic activity is reduced
Solution Approach 1:
The patent merges the inactive acid ceramidase precursor with a portion of fully active acid ceramidase in a single therapeutic formulation. This combination ensures immediate therapeutic effectiveness from the active enzyme while the inactive precursor provides sustained release and extended duration of action. The two forms work synergistically to overcome the limitations of using either form alone.
Solution Approach 2:
The patent creates a composite enzyme preparation consisting of multiple forms of acid ceramidase (inactive precursor and active enzyme) in specific ratios. This composite formulation combines the advantages of both forms: the stability and prolonged half-life of the inactive precursor with the immediate catalytic activity of the active enzyme, achieving enhanced overall therapeutic reliability.
3Duration of action of stationary object
If high ratio of inactive precursor to active enzyme is used, then sustained therapeutic effect is improved, but initial enzymatic activity is insufficient
Solution Approach 1:
The patent applies partial action by using a controlled proportion of active enzyme (not 100%) to provide sufficient initial therapeutic activity, while the remaining portion is in inactive precursor form to ensure sustained effect. This partial activation strategy balances immediate power requirements with long-term duration, avoiding the waste of converting all precursor to active form while ensuring adequate initial activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ceramidase mixture with a higher ratio of inactive precursor to active enzyme demonstrates enhanced effectiveness in promoting cell survival and improving cellular phenotypes, such as increased collagen 2 expression in chondrocytes, compared to preparations with higher active enzyme content.
Implementation Method 1
incubating a medium containing the inactive precursor under conditions that transform a portion of it into active acid ceramidase
Data Source
AI summary
The present invention relates to a therapeutic composition including a ceramidase mixture and a pharmaceutically acceptable carrier, where the ceramidase mixture includes an inactive acid ceramidase precursor and an active acid ceramidase. The invention also relates to a method of acid ceramidase treatment, including formulating the acid ceramidase used in said treatment as a ceramidase mixture, where the ceramidase mixture includes an inactive acid ceramidase precursor and an active acid ceramidase. The invention further relates to a method of producing a therapeutic composition including providing a medium containing an inactive acid ceramidase precursor; incubating the medium under conditions effective to transform a portion of the inactive acid ceramidase precursor to active acid ceramidase; and recovering the incubated medium as a ceramidase mixture comprising the inactive acid ceramidase precursor and an active acid ceramidase. The present invention also relates to preparation of a therapeutic composition of a ceramidase lacking acid sphingomyelinase.